Search Results for 'tdf hiv'

tdf hiv published presentations and documents on DocSlides.

Comparison of NNRTI vs NNRTI
Comparison of NNRTI vs NNRTI
by tatyana-admore
ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR...
Switch to EVG/c/FTC/TDF
Switch to EVG/c/FTC/TDF
by liane-varnes
STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Desi...
Fixed-Dose Combination of
Fixed-Dose Combination of
by myesha-ticknor
Doravirine. /Lamivudine/TDF is Non-Inferior to . ...
1 Fundación Huésped, Buenos Aires, Argentina;
1 Fundación Huésped, Buenos Aires, Argentina;
by aaron
2. Instituto Nacional de Ciencias Médicas y Nutr...
Comparison of NNRTI vs NNRTI
Comparison of NNRTI vs NNRTI
by lindy-dunigan
ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR...
ACTHIV 2018:  A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
by phoebe-click
ACTIVITY CODE . TD342. Antiretroviral Medications...
“On Demand” Oral PrEP: Lessons Learned from Macaque Models
“On Demand” Oral PrEP: Lessons Learned from Macaque Models
by giovanna-bartolotta
“On Demand” Oral PrEP: Lessons Learned from M...
Gilead Sciences, Inc., Foster City, CA, USA
Gilead Sciences, Inc., Foster City, CA, USA
by phoebe-click
Gilead Sciences, Inc., Foster City, CA, USA FTC/T...
Phase 2 of new ARVs Fostemsavir
Phase 2 of new ARVs Fostemsavir
by sportyinds
, . prodrug. of . temsavir. . (. attachment inhi...
Comparison of RTV vs Cobi
Comparison of RTV vs Cobi
by studmonkeybikers
GS-US-216-0114. . Gallant JE. JID 2013;208:32-9...
937401234123534671341849346744x 19 333133Webinar Requirements  A c
937401234123534671341849346744x 19 333133Webinar Requirements A c
by erica
HBcAbThis prescribe ARTART Dispensed0-5-14 Days0-1...
DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT
DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT
by jasmine
–. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RE...
Jeanne Marrazzo, MD, MPH
Jeanne Marrazzo, MD, MPH
by rose
Professor of Medicine. University of Washington. S...
HIV 2020:  Time for change
HIV 2020: Time for change
by garcia
Dr. Kay Mahomed. Netcare. Garden City Clinic. Ma...
Switching from TDF/FTC to TAF/
Switching from TDF/FTC to TAF/
by fanny
FTC. Study 311-1089. Switching from TDF/FTC to TAF...
Cases from the Clinic(ians):  Case-based Panel Discussion
Cases from the Clinic(ians): Case-based Panel Discussion
by tripp
Associate Dean for Global Health. University of Al...
CROI 2015: HIV Prevention Updates
CROI 2015: HIV Prevention Updates
by pamella-moone
Ruanne V Barnabas, . MBChB. . Dphil. Global Heal...
ID Week 2016: HIV Update
ID Week 2016: HIV Update
by min-jolicoeur
Robert Harrington, M.D.. ID Week 2016: HIV Update...
Second-Generation  HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazan
Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazan
by sherrill-nordquist
± . Ritonavir. Carey Hwang. ,. 1. Dirk Schürma...
Track B Workshop  Controversies in the Management of HIV-positive Adults:
Track B Workshop Controversies in the Management of HIV-positive Adults:
by natalia-silvester
A Case-Based Approach. Sasisopin Kiertiburanakul,...
Essentials for Optimal Care of HIV Patients
Essentials for Optimal Care of HIV Patients
by marina-yarberry
Evidence-Based Approaches. Simply Speaking. ®. ...
Treating and Preventing HIV in 2019: Interactive Cases From the Clinic(ians)
Treating and Preventing HIV in 2019: Interactive Cases From the Clinic(ians)
by alida-meadow
Treating and Preventing HIV in 2019: Interactive ...
PrEP to Prevent HIV and Promote Sexual Health
PrEP to Prevent HIV and Promote Sexual Health
by cheryl-pisano
PrEP to Prevent HIV and Promote Sexual Health www...
The Eras of the HIV Epidemic
The Eras of the HIV Epidemic
by relylancome
1981-1986. 1987-1995. 1996-2005. 2006-2011. 2012+....
HIV PREVENTION SAMU SUMMARY
HIV PREVENTION SAMU SUMMARY
by FluffyFace
2018. Objectives . To describe the current situati...
HIV Transmission  PrEP /
HIV Transmission PrEP /
by PeacefulPlace
nPEP. Mark Schweizer, DDS MPH. Director Infection ...
Optimizing HIV treatment
Optimizing HIV treatment
by anderson
Professor Francois Venter. Ezintsha, University of...
Susan P. Buchbinder, MD Director, Bridge HIV
Susan P. Buchbinder, MD Director, Bridge HIV
by harmony
San . Francisco Department . of Public Health. Cli...
Innovative Strategies for the Management
Innovative Strategies for the Management
by karlyn-bohler
of HIV Infection. Dual therapies without NRTIs. J...
CDC’s Interim Guidance on the Use of PrEP in Heterosexual
CDC’s Interim Guidance on the Use of PrEP in Heterosexual
by calandra-battersby
Adults:. . Implications . for Clinical Practice....
Comparison of INSTI vs PI
Comparison of INSTI vs PI
by conchita-marotz
FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . De...
Update on risk factors, detection, and management of neuroc
Update on risk factors, detection, and management of neuroc
by natalia-silvester
Scott Letendre, M.D.. Professor of . Medicine and...
Highlights of AIDS
Highlights of AIDS
by calandra-battersby
2016: Advances in . HIV Prevention, Care and Trea...
Comparison of INSTI vs INSTI
Comparison of INSTI vs INSTI
by pamella-moone
QDMRK. SPRING-2. ONCEMRK. ONCEMRK. Design. Object...
PrEP Training for
PrEP Training for
by tatyana-admore
Providers in Clinical Settings. 2. Welcome!. Plea...
A  Demonstration  Open Label
A Demonstration Open Label
by jane-oiler
Study to Assess the . Acceptability. , Safety. a...
ART for Prevention… What Happens Next?
ART for Prevention… What Happens Next?
by briana-ranney
Myron S. Cohen, MD. Yeargan-Bate Eminent Professo...
Characteristics and Oral
Characteristics and Oral
by lois-ondreau
PrEP. Adherence in the TDF2 Open-Label Extension...
ART in Resource-limited settings :
ART in Resource-limited settings :
by liane-varnes
Progress and Challenges. Dr. B. B. . Rewari. MD,...
ADOLESCENT  PrEP   STUDIES
ADOLESCENT PrEP STUDIES
by min-jolicoeur
. . Shorai. . Mukaka. , . MBchB. ...